abstract |
The present invention relates to: a novel compound exhibiting enteropeptidase inhibitory activity; a pharmaceutically acceptable salt thereof; a pharmaceutical composition for metabolic diseases such as obesity, diabetes, or hyperlipidemia, including the compound or a pharmaceutically acceptable salt thereof; and a method for preventing or treating metabolic diseases using the novel compound. The compound of the present invention enables, due to excellent enteropeptidase inhibitory activity, not only fats but also proteins to be excreted when ingested foods are excreted, not absorbed, from the body, resulting in fewer side effects such as fatty stool, and acts only on the gastrointestinal tract, thus reducing side effects such as depression. Thus, the compound of the present invention is very useful as an agent for the treatment or prevention of various metabolic diseases such as obesity, diabetes, and hyperlipidemia. |